
CLAIMS

1. A pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors:

Formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein:

W is O, N-H, N-(C_1-C_{10} alkyl) or S;

each X is independently CH or N;

R^1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O;


R^2 is LY;

each L is a direct bond, C_1-C_{10} alkylene, C_2-C_{10} alkenylene or C_2-C_{10} alkynylene;

Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and

each R^3 is independently H, C_1-C_{10} alkyl, halogen, fluoro C_1-C_{10} alkyl, O-C_1-C_{10} alkyl, NH-C_1-C_{10} alkyl, S-C_1-C_{10} alkyl, O-fluoro C_1-C_{10} alkyl, NH-acyl, NH-C(O)-NH-C_1-C_{10} alkyl, C(O)-NH-C_1-C_{10} alkyl, aryl or heteroaryl.

2. The composition according to claim 1, wherein R^1 is represented by any of the following structures:



3. The composition according to any one of claims 1 to 2, wherein R^1 is morpholine.

4. The composition according to any one of the preceding claims, wherein W is O or S.

5. The composition according to any one of the preceding claims, wherein W is O.


6. The composition according any one of the preceding claims, wherein X is CH.

7. The composition according to any one of the preceding claims, wherein R^3 is H.


8. The compositionaccording to any one of the preceding claims, wherein L is C_1-C_{10} alkylene.

9. The composition according to any one of the preceding claims, wherein Y contains one or two heteroatoms.

10. The composition according to any one of the preceding claims, wherein Y is selected from:



Formula A



Formula B

or

wherein:

A is selected from O, S, NR^4 or optionally substituted C_1-C_3 alkylene, C_2-C_3 alkenylene or C_2-C_3 alkynylene;

B is NR^4, O or CH_2;

wherein R^4 is H or optionally substituted C_1-C_{10} alkyl, C_2-C_{10} alkenyl or C_2-C_{10} alkynyl;

p is selected from 0 or 1;


each m is independently selected from 0, 1 or 2; and


each n is independently selected from 1, 2 or 3.


11. The composition according to claim 10, wherein A is O or C_1-C_3 alkylene.


12. The composition according to claim 10 or 11, wherein B is O or CH_2.


13. The composition according to any one of the preceding claims, wherein the compound of formula (I) is illustrated by any one of the following structures:


















14. The composition according to claim 13, wherein thecompound of formula (I) is:



or a pharmaceutically acceptable salt thereof.

15. The composition according to any one of the preceding claims, wherein the second agent is selected from a proteasome inhibitor, a p70S6K inhibitor, a BTK and Tec family inhibitor and a MEK1 inhibitor.

16. The composition according to any one of the preceding claims, wherein the second agent is selected from Bortezomib, LY2584702, Ibrutinib and Selumetinib.

17. A pharmaceutical composition comprising a composition as defined in any one of the preceding claims, and a pharmaceutically acceptable excipient.

18. Use of a composition according to any one of claims 1 to 17 for the manufacture of a medicament for use in therapy, wherein the therapy is of cancer.

19. The use according to claim 18, wherein the cancer involves a solid tumour or is a haematological cancer.

20. The use according to claim 18, wherein the cancer is a leukaemia or a PTEN-negative solid tumour.

21. A therapeutically effective amount of at least one compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors, for use in treating or preventing a condition in a patient.